UBS Group
XTNT icon

UBS Group’s Xtant Medical Holdings XTNT Stock Holding History

UBS Group’s Portfolio XTNT Stock Details XTNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8
Closed -$6 – 11263
2025
Q4 		$6 Sell
8
-387
-98% -$281 ﹤0.01% 10401
2025
Q3 		$257 Buy
395
+394
+39,400% +$249 ﹤0.01% 9775
2025
Q2 		$1 Hold
1
– – ﹤0.01% 10197
2025
Q1 		$0 Hold
1
– – ﹤0.01% 10777
2024
Q4 		$0 Sell
1
-39,047
-100% -$18.9K ﹤0.01% 10486
2024
Q3 		$26.4K Buy
39,048
+31,239
+400% +$20.7K ﹤0.01% 7192
2024
Q2 		$4.92K Sell
7,809
-634
-8% -$506 ﹤0.01% 8040
2024
Q1 		$9.88K Buy
8,443
+8,351
+9,077% +$9.16K ﹤0.01% 7262
2023
Q4 		$104 Sell
92
-4,127
-98% -$4.85K ﹤0.01% 8929
2023
Q3 		$4.64K Buy
+4,219
New +$4.53K ﹤0.01% 7427
2023
Q2 		– Sell
-7,063
Closed -$4.5K – 9756
2023
Q1 		$4.5K Buy
7,063
+5,712
+423% +$4.17K ﹤0.01% 8181
2022
Q4 		$892 Buy
+1,351
New +$883 ﹤0.01% 10043
2022
Q3 		– Sell
-4,888
Closed -$3K – 11011
2022
Q2 		$3K Buy
+4,888
New +$2.89K ﹤0.01% 9379
2022
Q1 		– Sell
-44,720
Closed -$25K – 10991
2021
Q4 		$25K Buy
+44,720
New +$42.1K ﹤0.01% 7596
2021
Q1 		– Sell
-1,262
Closed -$2K – 9546
2020
Q4 		$2K Buy
+1,262
New +$1.63K ﹤0.01% 8125
2020
Q3 		– Sell
-1,174
Closed -$1K – 8462
2020
Q2 		$1K Sell
1,174
-9,914
-89% -$9.09K ﹤0.01% 7808
2020
Q1 		$7K Buy
+11,088
New +$13.4K ﹤0.01% 7165
2019
Q1 		– Sell
-1,887
Closed -$3K – 8233
2018
Q4 		$3K Buy
1,887
+1,159
+159% +$3.74K ﹤0.01% 7741
2018
Q3 		$3K Sell
728
-7,724
-91% -$40.8K ﹤0.01% 7673
2018
Q2 		$47K Buy
8,452
+4,611
+120% +$30.8K ﹤0.01% 6020
2018
Q1 		$30K Sell
3,841
-1,826
-32% -$12K ﹤0.01% 6090
2017
Q4 		$39K Sell
5,667
-1,583
-22% -$12.5K ﹤0.01% 6045
2017
Q3 		$63K Sell
7,250
-1,009
-12% -$9.02K ﹤0.01% 5632
2017
Q2 		$65K Sell
8,259
-979
-11% -$6.51K ﹤0.01% 5475
2017
Q1 		$69K Buy
9,238
+1,298
+16% +$7.98K ﹤0.01% 5294
2016
Q4 		$53K Buy
7,940
+4,857
+158% +$41.9K ﹤0.01% 5790
2016
Q3 		$42K Sell
3,083
-457
-13% -$8.41K ﹤0.01% 5657
2016
Q2 		$81K Buy
3,540
+3,349
+1,753% +$86.3K ﹤0.01% 5183
2016
Q1 		$6K Sell
191
-11
-5% -$351 ﹤0.01% 6939
2015
Q4 		$7K Buy
+202
New +$7.1K ﹤0.01% 7535
2015
Q2 		– Sell
-9
Closed – – 8891
2015
Q1 		$0 Sell
9
-151
-94% -$6.08K ﹤0.01% 9465
2014
Q4 		$6K Buy
+160
New +$6.66K ﹤0.01% 8863

Other funds holding XTNT

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS Group's XTNT Position: Q1 2026 in Review

UBS Group sold out of Xtant Medical Holdings (XTNT) in Q1 2026, closing a stake of 8 shares — an estimated $6 sold.

UBS Group first reported a position in XTNT in Q4 2014 and held it in 32 quarters. The position peaked at $81K in Q2 2016. 34 funds tracked by Wall St. Rank hold XTNT as of Q1 2026.

  • UBS Group reported no remaining Xtant Medical Holdings position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 8 Xtant Medical Holdings shares in Q1 2026, an estimated $6.
  • UBS Group first reported a position in Xtant Medical Holdings in Q4 2014 and held it in 32 quarters.
  • UBS Group's Xtant Medical Holdings position peaked at $81K in Q2 2016.
  • 34 funds tracked by Wall St. Rank held Xtant Medical Holdings as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.